{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:17:59Z","timestamp":1782325079026,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11060-025-05194-8","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:56:02Z","timestamp":1754913362000},"page":"1131-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic antitumor and radiosensitizing effects of \u03b1-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K\/Akt inhibition and DNA repair impairment in glioblastoma"],"prefix":"10.1007","volume":"175","author":[{"given":"Takayuki","family":"Nishiwaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urara","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Kuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Harakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukka","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Izumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Shimazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"5194_CR1","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/jco.2007.11.8554","volume":"25","author":"R Stupp","year":"2007","unstructured":"Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127\u20134136. https:\/\/doi.org\/10.1200\/jco.2007.11.8554","journal-title":"J Clin Oncol"},{"key":"5194_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijrobp.2021.05.001","volume":"111","author":"R Singh","year":"2021","unstructured":"Singh R, Lehrer EJ, Wang M, Perlow HK, Zaorsky NG, Trifiletti DM, Bovi J, Navarria P, Scoccianti S, Gondi V, Brown PD, Palmer JD (2021) Dose escalated radiation therapy for glioblastoma multiforme: an international systematic review and Meta-Analysis of 22 prospective trials. Int J Radiat Oncol Biol Phys 111:371\u2013384. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5194_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant Temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/s1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"5194_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F, Navarria P, Belka C (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36. https:\/\/doi.org\/10.1186\/s13014-021-01767-9","journal-title":"Radiat Oncol"},{"key":"5194_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00701-011-1228-6","volume":"154","author":"A Siu","year":"2012","unstructured":"Siu A, Wind JJ, Iorgulescu JB, Chan TA, Yamada Y, Sherman JH (2012) Radiation necrosis following treatment of high grade glioma\u2013a review of the literature and current Understanding. Acta Neurochir (Wien) 154:191\u2013201 discussion 201. https:\/\/doi.org\/10.1007\/s00701-011-1228-6","journal-title":"Acta Neurochir (Wien)"},{"key":"5194_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1248\/cpb.46.684","volume":"46","author":"K Ohta","year":"1998","unstructured":"Ohta K, Mizushina Y, Hirata N, Takemura M, Sugawara F, Matsukage A, Yoshida S, Sakaguchi K (1998) Sulfoquinovosyldiacylglycerol, KM043, a new potent inhibitor of eukaryotic DNA polymerases and HIV-reverse transcriptase type 1 from a marine red alga, gigartina Tenella. Chem Pharm Bull (Tokyo) 46:684\u2013686. https:\/\/doi.org\/10.1248\/cpb.46.684","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"5194_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/bjc.1997.54","volume":"75","author":"H Sahara","year":"1997","unstructured":"Sahara H, Ishikawa M, Takahashi N, Ohtani S, Sato N, Gasa S, Akino T, Kikuchi K (1997) In vivo anti-tumour effect of 3\u2019-sulphonoquinovosyl 1\u2019-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 75:324\u2013332. https:\/\/doi.org\/10.1038\/bjc.1997.54","journal-title":"Br J Cancer"},{"key":"5194_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1349-7006.2000.tb00887.x","volume":"91","author":"S Hanashima","year":"2000","unstructured":"Hanashima S, Mizushina Y, Ohta K, Yamazaki T, Sugawara F, Sakaguchi K (2000) Structure-activity relationship of a novel group of mammalian DNA polymerase inhibitors, synthetic sulfoquinovosylacylglycerols. Jpn J Cancer Res 91:1073\u20131083. https:\/\/doi.org\/10.1111\/j.1349-7006.2000.tb00887.x","journal-title":"Jpn J Cancer Res"},{"key":"5194_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1349-7006.2002.tb01204.x","volume":"93","author":"H Sahara","year":"2002","unstructured":"Sahara H, Hanashima S, Yamazaki T, Takahashi S, Sugawara F, Ohtani S, Ishikawa M, Mizushina Y, Ohta K, Shimozawa K, Gasa S, Jimbow K, Sakaguchi K, Sato N, Takahashi N (2002) Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin\u2019s natural sulfonoquinovosylmonoacylglycerols. Jpn J Cancer Res 93:85\u201392. https:\/\/doi.org\/10.1111\/j.1349-7006.2002.tb01204.x","journal-title":"Jpn J Cancer Res"},{"key":"5194_CR10","first-page":"4397","volume":"30","author":"K Ohta","year":"2010","unstructured":"Ohta K, Murata H, Mori Y, Ishima M, Sugawara F, Sakaguchi K, Miura M (2010) Remodeling of the tumor microenvironment by combined treatment with a novel radiosensitizer, {alpha}-sulfoquinovosylmonoacylglycerol ({alpha}-SQMG) and X-irradiation. Anticancer Res 30:4397\u20134404","journal-title":"Anticancer Res"},{"key":"5194_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1006\/bbrc.2001.5852","volume":"288","author":"K Ohta","year":"2001","unstructured":"Ohta K, Mizushina Y, Yamazaki T, Hanashima S, Sugawara F, Sakaguchi K (2001) Specific interaction between an oligosaccharide on the tumor cell surface and the novel antitumor agents, sulfoquinovosylacylglycerols. Biochem Biophys Res Commun 288:893\u2013900. https:\/\/doi.org\/10.1006\/bbrc.2001.5852","journal-title":"Biochem Biophys Res Commun"},{"key":"5194_CR12","doi-asserted-by":"publisher","unstructured":"Varricchio A, Khan S, Price ZK, Davis RA, Ramesh SA, Yool AJ (2023) Pharmacological inhibition of membrane signaling mechanisms reduces the invasiveness of U87-MG and U251-MG glioblastoma cells in vitro. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15041027","DOI":"10.3390\/cancers15041027"},{"key":"5194_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3171\/2019.12.Jns192682","volume":"134","author":"T Yamada","year":"2021","unstructured":"Yamada T, Tsuji S, Nakamura S, Egashira Y, Shimazawa M, Nakayama N, Yano H, Iwama T, Hara H (2021) Riluzole enhances the antitumor effects of Temozolomide via suppression of MGMT expression in glioblastoma. J Neurosurg 134:701\u2013710. https:\/\/doi.org\/10.3171\/2019.12.Jns192682","journal-title":"J Neurosurg"},{"key":"5194_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11060-022-04154-w","volume":"160","author":"S Tsuji","year":"2022","unstructured":"Tsuji S, Nakamura S, Shoda K, Yamada T, Shimazawa M, Nakayama N, Iwama T, Hara H (2022) NMDA receptor signaling induces the chemoresistance of Temozolomide via upregulation of MGMT expression in glioblastoma cells. J Neurooncol 160:375\u2013388. https:\/\/doi.org\/10.1007\/s11060-022-04154-w","journal-title":"J Neurooncol"},{"key":"5194_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3171\/2019.12.JNS192682","volume":"134","author":"T Yamada","year":"2020","unstructured":"Yamada T, Tsuji S, Nakamura S, Egashira Y, Shimazawa M, Nakayama N, Yano H, Iwama T, Hara H (2020) Riluzole enhances the antitumor effects of Temozolomide via suppression of MGMT expression in glioblastoma. J Neurosurg 134:701\u2013710. https:\/\/doi.org\/10.3171\/2019.12.JNS192682","journal-title":"J Neurosurg"},{"key":"5194_CR16","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1158\/0008-5472.Can-05-2209","volume":"66","author":"I Sakimoto","year":"2006","unstructured":"Sakimoto I, Ohta K, Yamazaki T, Ohtani S, Sahara H, Sugawara F, Sakaguchi K, Miura M (2006) Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 66:2287\u20132295. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-2209","journal-title":"Cancer Res"},{"key":"5194_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/00498254.2018.1448949","volume":"49","author":"T Ruike","year":"2019","unstructured":"Ruike T, Kanai Y, Iwabata K, Matsumoto Y, Murata H, Ishima M, Ohta K, Oshige M, Katsura S, Kuramochi K, Kamisuki S, Sahara H, Miura M, Sugawara F, Sakaguchi K (2019) Distribution and metabolism of (14)C-sulfoquinovosylacylpropanediol ((14)C-SQAP) after a single intravenous administration in tumor-bearing mice. Xenobiotica 49:346\u2013362. https:\/\/doi.org\/10.1080\/00498254.2018.1448949","journal-title":"Xenobiotica"},{"key":"5194_CR18","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1158\/0008-5472.Can-18-1654","volume":"78","author":"Y Takakusagi","year":"2018","unstructured":"Takakusagi Y, Naz S, Takakusagi K, Ishima M, Murata H, Ohta K, Miura M, Sugawara F, Sakaguchi K, Kishimoto S, Munasinghe JP, Mitchell JB, Krishna MC (2018) A multimodal molecular imaging study evaluates Pharmacological alteration of the tumor microenvironment to improve radiation response. Cancer Res 78:6828\u20136837. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-1654","journal-title":"Cancer Res"},{"key":"5194_CR19","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/mto.2015.20","volume":"2","author":"H Iwamoto","year":"2015","unstructured":"Iwamoto H, Nakamura T, Koga H, Izaguirre-Carbonell J, Kamisuki S, Sugawara F, Abe M, Iwabata K, Ikezono Y, Sakaue T, Masuda A, Yano H, Ohta K, Nakano M, Shimose S, Shirono T, Torimura T (2015) Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces angiogenic switch off in a hepatoma mouse model. Mol Ther Oncolytics 2:15020. https:\/\/doi.org\/10.1038\/mto.2015.20","journal-title":"Mol Ther Oncolytics"},{"key":"5194_CR20","doi-asserted-by":"publisher","first-page":"503703","DOI":"10.1016\/j.mrgentox.2023.503703","volume":"892","author":"J Maeda","year":"2023","unstructured":"Maeda J, Shellenberger KD, Kurihara W, Haga T, Kato TA (2023) Sulfoquinovosyl acylpropanediol (SQAP): Inhibition of Poly (ADP-ribose) metabolism and enhanced cytotoxicity in homologous recombination repair-deficient Chinese hamster-derived cells. Mutat Res Genet Toxicol Environ Mutagen 892:503703. https:\/\/doi.org\/10.1016\/j.mrgentox.2023.503703","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"5194_CR21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/iju.12753","volume":"22","author":"Y Sawada","year":"2015","unstructured":"Sawada Y, Omoto K, Kohei N, Sakaguchi K, Miura M, Tanabe K (2015) Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer. Int J Urol 22:590\u2013595. https:\/\/doi.org\/10.1111\/iju.12753","journal-title":"Int J Urol"},{"key":"5194_CR22","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.tranon.2021.101285","volume":"15","author":"Y Takakusagi","year":"2022","unstructured":"Takakusagi Y, Sugyo A, Tsuji AB, Sudo H, Yasunaga M, Matsumura Y, Sugawara F, Sakaguchi K, Higashi T (2022) The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3. Transl Oncol 15:101285. https:\/\/doi.org\/10.1016\/j.tranon.2021.101285","journal-title":"Transl Oncol"},{"key":"5194_CR23","doi-asserted-by":"publisher","first-page":"15136","DOI":"10.1038\/srep15136","volume":"5","author":"J Izaguirre-Carbonell","year":"2015","unstructured":"Izaguirre-Carbonell J, Kawakubo H, Murata H, Tanabe A, Takeuchi T, Kusayanagi T, Tsukuda S, Hirakawa T, Iwabata K, Kanai Y, Ohta K, Miura M, Sakaguchi K, Matsunaga S, Sahara H, Kamisuki S, Sugawara F (2015) Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity. Sci Rep 5:15136. https:\/\/doi.org\/10.1038\/srep15136","journal-title":"Sci Rep"},{"key":"5194_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/cac2.12361","volume":"42","author":"E Verdugo","year":"2022","unstructured":"Verdugo E, Puerto I, Medina M (2022) An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond) 42:1083\u20131111. https:\/\/doi.org\/10.1002\/cac2.12361","journal-title":"Cancer Commun (Lond)"},{"key":"5194_CR25","doi-asserted-by":"publisher","first-page":"33440","DOI":"10.18632\/oncotarget.7961","volume":"7","author":"X Li","year":"2016","unstructured":"Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:33440\u201333450. https:\/\/doi.org\/10.18632\/oncotarget.7961","journal-title":"Oncotarget"},{"key":"5194_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y (2020) PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11:797. https:\/\/doi.org\/10.1038\/s41419-020-02998-6","journal-title":"Cell Death Dis"},{"key":"5194_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/s0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96:857\u2013868. https:\/\/doi.org\/10.1016\/s0092-8674(00)80595-4","journal-title":"Cell"},{"key":"5194_CR28","doi-asserted-by":"publisher","first-page":"11598","DOI":"10.1073\/pnas.181181198","volume":"98","author":"LD Mayo","year":"2001","unstructured":"Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase\/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98:11598\u201311603. https:\/\/doi.org\/10.1073\/pnas.181181198","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5194_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1101-973","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC (2001) HER-2\/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3:973\u2013982. https:\/\/doi.org\/10.1038\/ncb1101-973","journal-title":"Nat Cell Biol"},{"key":"5194_CR30","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","volume":"12","author":"JA Diehl","year":"1998","unstructured":"Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates Cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499\u20133511. https:\/\/doi.org\/10.1101\/gad.12.22.3499","journal-title":"Genes Dev"},{"key":"5194_CR31","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1128\/mcb.25.13.5725-5737.2005","volume":"25","author":"K Katayama","year":"2005","unstructured":"Katayama K, Fujita N, Tsuruo T (2005) Akt\/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2\/M transition. Mol Cell Biol 25:5725\u20135737. https:\/\/doi.org\/10.1128\/mcb.25.13.5725-5737.2005","journal-title":"Mol Cell Biol"},{"key":"5194_CR32","first-page":"335","volume":"5","author":"LA Porter","year":"2003","unstructured":"Porter LA, Donoghue DJ (2003) Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 5:335\u2013347","journal-title":"Prog Cell Cycle Res"},{"key":"5194_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4161\/cc.2.4.433","volume":"2","author":"J Liang","year":"2003","unstructured":"Liang J, Slingerland JM (2003) Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339\u2013345","journal-title":"Cell Cycle"},{"key":"5194_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1158\/1535-7163.Mct-07-2200","volume":"7","author":"M Toulany","year":"2008","unstructured":"Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M, Rodemann HP (2008) Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7:1772\u20131781. https:\/\/doi.org\/10.1158\/1535-7163.Mct-07-2200","journal-title":"Mol Cancer Ther"},{"key":"5194_CR35","first-page":"753","volume":"31","author":"K Fujiwara","year":"2007","unstructured":"Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y (2007) Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 31:753\u2013760","journal-title":"Int J Oncol"},{"key":"5194_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/neuonc\/nop059","volume":"12","author":"E Chautard","year":"2010","unstructured":"Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, Morel L, Verrelle P (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 12:434\u2013443. https:\/\/doi.org\/10.1093\/neuonc\/nop059","journal-title":"Neuro Oncol"},{"key":"5194_CR37","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on Serine 139. J Biol Chem 273:5858\u20135868. https:\/\/doi.org\/10.1074\/jbc.273.10.5858","journal-title":"J Biol Chem"},{"key":"5194_CR38","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1016\/j.febslet.2013.08.028","volume":"587","author":"WZ Tu","year":"2013","unstructured":"Tu WZ, Li B, Huang B, Wang Y, Liu XD, Guan H, Zhang SM, Tang Y, Rang WQ, Zhou PK (2013) \u03b3H2AX foci formation in the absence of DNA damage: mitotic H2AX phosphorylation is mediated by the DNA-PKcs\/CHK2 pathway. FEBS Lett 587:3437\u20133443. https:\/\/doi.org\/10.1016\/j.febslet.2013.08.028","journal-title":"FEBS Lett"},{"key":"5194_CR39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.onc.1209863","volume":"26","author":"S Burdak-Rothkamm","year":"2007","unstructured":"Burdak-Rothkamm S, Short SC, Folkard M, Rothkamm K, Prise KM (2007) ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells. Oncogene 26:993\u20131002. https:\/\/doi.org\/10.1038\/sj.onc.1209863","journal-title":"Oncogene"},{"key":"5194_CR40","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.18632\/aging.101917","volume":"11","author":"E B\u00e1rtov\u00e1","year":"2019","unstructured":"B\u00e1rtov\u00e1 E, Legartov\u00e1 S, Dundr M, Such\u00e1nkov\u00e1 J (2019) A role of the 53BP1 protein in genome protection: structural and functional characteristics of 53BP1-dependent DNA repair. Aging 11:2488\u20132511. https:\/\/doi.org\/10.18632\/aging.101917","journal-title":"Aging"},{"key":"5194_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12318","volume":"499","author":"A Fradet-Turcotte","year":"2013","unstructured":"Fradet-Turcotte A, Canny MD, Escribano-D\u00edaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D (2013) 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature 499:50\u201354. https:\/\/doi.org\/10.1038\/nature12318","journal-title":"Nature"},{"key":"5194_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12318","volume":"499","author":"A Fradet-Turcotte","year":"2013","unstructured":"Fradet-Turcotte A, Canny MD, Escribano-D\u00edaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D (2013) 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature 499:50\u201354. https:\/\/doi.org\/10.1038\/nature12318","journal-title":"Nature"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05194-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:09:45Z","timestamp":1759993785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05194-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5194"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05194-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6896488\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Animal Experiment Committee of Gifu University, Japan (Ethics No. AG-P-N-20240062), reviewed and approved all animal procedures. The experiments were conducted in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}